Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study

Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study / D'Angelo, S.; Tirri, E.; Giardino, A. M.; Derosa, T.; Matucci Cerinic, M.; Dagna, L.; Santo, L.; Ciccia, F.; Frediani, B.; Govoni, M.; Pallavicini, F. B.; Grembiale, R. D.; Sedie, A. D.; Mule, R.; Cantatore, F. P.; Foti, R.; Gremese, E.; Conigliaro, P.; Salaffi, F.; Viapiana, O.; Cauli, A.; Giacomelli, R.; Arcarese, L.; Guggino, G.; Russo, R.; Puenpatom, A.; Capocotta, D.; Nacci, F.; Anelli, M. G.; Picerno, V.; Binetti, C.; Iannone, F.. - In: INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES. - ISSN 1756-1841. - 27:3(2024). [10.1111/1756-185X.15091]